Podcasts about Leukemia

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Featured Article:Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Diagnosed with cancer at 16, Emily hadn't dared hope she would graduate from high school or college, let alone fall in love and get engaged.  

Watch Delta's heartwarming reunion with her dad at St. Jude go viral, capturing the hearts of millions as she battles leukemia.

The former St. Jude patient treated for cancer and sickle cell disease says her health journey helped her become determined, strong and hopeful.

There are calls for greater transparency about how Pharmac prioritises medicines on what is effectively a wait list for funding as it considers culling that list. If the proposal goes ahead the government drug buying agency will focus on cutting drugs that have been in the lowest ranked group on the options for funding list for more than two years. Publicly drugs on the funding wait list appear in alphabetical order; but where they are ranked in terms of priority for funding is kept secret. Leukemia and Blood Cancer chief executive Tim Edmonds spoke to Lisa Owen.

Dr. Hiroto Inaba was raised in a rural province in Japan to honor his samurai heritage. His parents taught him the “Bushido” that an honorable life is one that upholds “the good fight,” Inaba says. After he lost his mother to cancer, he decided his fight would be as an oncologist tackling cancer.

Trick-or-treaters Leave Their Halloween Candy For Child Battling LeukemiaA search for hope at the end of this very anxious week led me to this humble bundle.  Zoe, 3, is the proud product of TJ and Courtney Thomas of Atlanta, Georgia.Back in February, Zoe was diagnosed with leukemia. And because her immune system is now compromised, she couldn't go trick-or-treating on Halloween with all the other kids. In fact, her parents even had to put up a sign to keep other kids away. The sign read: "Sorry, no candy. Child with cancer. See you next year!""The whole purpose was just so that we wouldn't have to keep telling kids 'sorry' and have disappointed kids," Zoe's mother Courtney Thomas said. "Never expected anything like this."How to connect with AgileDad:- [website] https://www.agiledad.com/- [instagram] https://www.instagram.com/agile_coach/- [facebook] https://www.facebook.com/RealAgileDad/- [Linkedin] https://www.linkedin.com/in/leehenson/

In this Review Series episode, Associate Editor Dr. Philippe Armand speaks with multiple authors about what it might look like to improve treatments follicular lymphoma, a disease that has been put on the backburner of innovation due to its generally treatable nature. Dr. Armand discusses "Treatment of relapsed and refractory follicular lymphoma: which treatment for which patient for which line of therapy?" with author Dr. Carla Casulo,  "The future of follicular lymphoma management: strategies on the horizon” with author Dr. Sarah C. Rutherford, and "An updated understanding of follicular lymphoma transformation” with Dr. Erin M. Parry.Find the whole review series on follicular lymphoma in volume 146 issue 15 of Blood Journal.  

Watch on YouTube Hemogenyx #HEMO has been given clearance to proceed with the next stage of testing in regard to its HG-CT1 therapy, which is designed to treat leukemia. Hemogenyx's chief executive Vladislav Sandler joins us to talk about the implications of continuing the trials, how they will be structured, and widened with the addition of testing for a group of 12-18 year olds.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Acute Myelogenous Leukemia (AML)⁠⁠⁠⁠⁠ from the Oncology section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Leukemia Awareness Month with guest Dr. Nikolai Podoltsev September 28, 2025 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

How do childhood experiences or cultural norms shape a woman's relationship with money?How can someone start rewriting their money story, especially if they feel stuck or ashamed? My guest, Michelle Taylor, has those answers and more for us today.At age 17, she overcame the adversity of Leukemia and launched her business at 27.Michelle shares how that life-changing experience shaped her approach to financial resilience and entrepreneurship.She has dedicated her career to helping women break through limiting beliefs about money, build lasting financial security, and finally feel in control.Through The Women Wealth Initiative, she offers more than advice; she offers a system, a strategy, and a supportive community to help you unlock your full financial potential.Michelle holds a Bachelor's in Business Administration and Marketing, and has been nationally recognized as a leader in financial planning. CONNECT WITH MICHELLE:Instagram - https://www.instagram.com/women_in_wealth/?hl=enLinkedIn - https://www.linkedin.com/in/michelle-taylor-9b396139CONNECT WITH DEBIDo you feel stuck?  Do you sense it's time for a change, but are unsure where to start or how to move forward? Schedule a clarity call!Free Clarity Call: https://calendly.com/debironca/free-clarity-callWebsite – https://www.debironca.comInstagram - @debironcaEmail – info@debironca.com Check out my online course!Your Story's Changing, Finding Purpose in Life's Transitionshttps://course.sequoiatransitioncoaching.com/8-week-programThe Family Letter by Debi Ronca – International Best Sellerhttps://www.amazon.com/dp/B07SSJFXBD

Lurie Children's Hospital has received $4 million from pediatric cancer foundation Cal's Angels to establish the Cal's Angels Advanced Leukemia Clinical and Research Program.

Lurie Children's Hospital has received $4 million from pediatric cancer foundation Cal's Angels to establish the Cal's Angels Advanced Leukemia Clinical and Research Program.

Lurie Children's Hospital has received $4 million from pediatric cancer foundation Cal's Angels to establish the Cal's Angels Advanced Leukemia Clinical and Research Program.

In this week's episode of the Blood Podcast, Associate Editor Dr. James Griffin interviews Drs. Binod Dhakal and Ruben Bierings about their respective papers published in this week's issue of Blood. Dr. Dhakal presents his study on using talquetamab, a bispecific antibody, as a bridging therapy before BCMA-targeted CAR T-cell therapy in multiple myeloma patients, showing promising results with high response rates and manageable toxicities. Next, Dr. Bierings identified patients with genetic variants in the guanine exchange factor MAP kinase–activating death domain (MADD) that impair VWF secretion from endothelial cells and possibly cause VWD type 1. Featured ArticlesA novel cause of type 1 von Willebrand disease: impaired exocytosis of Weibel-Palade bodies due to biallelic MADD variantsSophie Hordijk, Stijn A. Groten, Petra E. Bürgisser, Sebastiaan N. J. Laan, Georg Christoph Korenke, Tomáš Honzík, Diane Beysen, Frank W. G. Leebeek, Paul A. Skehel, Maartje van den Biggelaar, Tom Carter, Ruben BieringsSequential targeting in multiple myeloma: talquetamab, a GPRC5D bispecific antibody, as a bridge to BCMA CAR-T therapyBinod Dhakal, Othman S. Akhtar, David Fandrei, Alexandria Jensen, Rahul Banerjee, Darren Pan, Shambavi Richard, Reed Friend, Matthew Rees, Patrick Costello, Mariola Vazquez Martinez, Oren Pasvolsky, Charlotte Wagner, James A. Davis, Omar Castaneda Puglianini, Ran Reshef, Aimaz Afrough, Danai Dima, Manisha Bhutani, Omar Nadeem, Ricardo Parrondo, Ciara Freeman, Lekha Mikkilineni, Shahzad Raza, Larry D. Anderson Jr, Prashant Kapoor, Hitomi Hosoya, Saurabh Chhabra, Ariel Grajales-Cruz, Mahmoud Gaballa, Shonali Midha, Melissa Alsina, Douglas Sborov, Krina Patel, Yi Lin, Christopher Ferreri, Nico Gagelmann, Anupama Kumar, Doris Hansen, Andrew Cowan, Luciano J. Costa, Maximilian Merz, Surbhi Sidana

See omnystudio.com/listener for privacy information.

Monday 20th October 2025 Simon's back on hosting duties with Vici this week joined by Tom Radonic, a local Perth ultra runner fresh off his recent challenge “Mund Everest” - comprising of 42 laps of Australia's toughest parkrun course Mundy Regional Park parkrun (210km and the equivalent elevation of Mount Everest). The challenge was in honour of Jeff Hansen - a pillar of the trail and parkrun community who very sadly passed away from Leukemia. Tom has already raised an incredible $13k for the Leukemia Foundation.  In local results, we had the Pemby Trail Festival, and the first Strive Meet of the season with Program A that included the 400m and 1500m We find out whether we can run as fast as Adam Kopp, whether Vici should go see Mariah Carey or run 25 laps in Cannington this Friday, we might finally hear about Jack Daniels in Vici's verbalisations, we debate on whether a PB is real if it's not in a legitimate race, and we shout out Holly Ranson for her 24hr run and Luke Taylor running for Prem babies who are this week's weapons of WARP.  Donate to the Jeff Hansen Challenge: https://fundraise.leukaemia.org.au/fundraiser/tomradonic1631  Donate to Luke Taylor's Running for Premature Babies https://www.runningforprematurebabies.com/fundraisers/lukestreadmillworldrecordrun/lets-celebrate    Reach out and connect! Instagram: @warunningpod Email: warunningpodcast@gmail.com Strava: https://www.strava.com/clubs/WARP    

In this Spotlight series episode on Acute Myeloid Leukemia, Blood Editor, Dr. Selina Luger interviews Drs. Laura Michaelis and Alexander Perl on their paper in the series titled “The fit older adult with acute myeloid leukemia: clinical challenges to providing evidence-based frontline treatment”. The conversation explores challenges in treating AML across different patient populations. They also focus on treatment approaches for fit older adults with AML, highlighting the need for less toxic therapies and ongoing randomized trials to better understand treatment efficacy. See the full spotlight series on Acute Myeloid Leukemia in Volume 145 Issue 24 of Blood journal. 

In this week's episode we'll learn more about a study comparing busulfan-melphalan with melphalan alone as the conditioning protocol for newly diagnosed, transplant-eligible multiple myeloma; then we will discuss data on how three-dimensional transcriptomics can reveal complex interactions between plasma cells and bone marrow microenvironments.Featured ArticlesHigh-dose busulfan-melphalan vs melphalan and reinforced VRD for newly diagnosed multiple myeloma: a phase 3 GEM trialProfiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomicsPreclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma

Morning Prayer (people who with leukemia, people who have lost loved ones) #prayer #jesus #god #aimingforjesus #peace #leukemia #death #loss Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

In this episode of I Am Refocused Radio, host Shemaiah Reed sits down with entrepreneur and commercial real estate powerhouse Chuck Cuda, founder of OPES Commercial Real Estate and CEO of Elevation Cannabis.As CEO of Elevation Cannabis, he expanded operations from five to 22 licenses across three states, proving his ability to grow and disrupt industries.But Chuck's success doesn't stop at business. In 2018, he founded the OPES Charitable Foundation, which has raised more than $3 million for causes like cancer research and autism awareness. He also serves on local boards — including the Leukemia and Lymphoma Society — and mentors young athletes through youth baseball, helping shape the next generation of leaders.This conversation dives deep into leadership, innovation, giving back, and what it really takes to build something that lasts.Become a supporter of this podcast: https://www.spreaker.com/podcast/i-am-refocused-radio--2671113/support.Thank you for tuning in to I Am Refocused Radio. For more inspiring conversations, visit IAmRefocusedRadio.com and stay connected with our community.Don't miss new episodes—subscribe now at YouTube.com/@RefocusedRadio

The government just announced a warning label will be added to Tylenol that use during pregnancy may be associated with an increased risk of Autism and ADHD in children..  In this episode, we talk about:—How the makers of Tylenol admitted in their own  internal documents that there is a strong correlation between Tylenol and Autism. —Why Tylenol's interference with the Liver's capability of making Glutathione is the mechanism  behind Tylenol contributing to neurological issues.  And how a rash on babies after giving them Tylenol after vaccination can be a signal that something has gone wrong with the Liver.—The reason Dr. Prather says that Tylenol causes damage to the Kidneys, Liver, and Gut every time you take it.  And the long list of potential harm that Tylenol can cause, including:  Liver damage, Kidney damage, G.I. bleeding, Diarrhea, Vomiting, Heart failure, Heart attacks, Hypertension, Undescended testicles, Asthma, and an increased chance of Cancers like Leukemia. —The benefits of Fever to the body and why Dr. Prather says there is "a tremendous amount of really good things that happen with a Fever."  And why the approach to just suppress a Fever leads to more problems and worse results.—How Fever is an indication of a Neurology issue and can actually reveal a lot of helpful diagnostic information.  And how Chiropractic is the way to deal with Neurological situations, including Fevers.—The chances of seizures from a Fever are not decreased by Tylenol, but Structure-Function Care can help the body avoid seizures by keeping the body in Homeostasis.  And how Tylenol is not only dangerous, but research shows it also has very little effectiveness for pain. —The Spleen-21 Acupuncture point that Dr. Prather's staff immediately request treatment on when they start to feel sick.  And the "really excellent" Elderberry and Vitamin C syrup that is very easy for children to take when they are ill.—Why Dr. Prather says that Homeopathy is "extremely effective for children" and is always safe.  And how it is "the best and safest way to help a child's immune system work better".—The Diathermy treatment Dr. Prather uses in his office to bring immediate relief to crying children with ear infections and "usually clears up the ear discomfort in one session".  And the gentle Galbreath maneuver Dr. Prather teaches Moms to do on their babies to promote ear drainage. —How Dr. Prather says that Autism can be reversed and how he has seen "really strong changes in Autism and ADHD".  And the methods that Holistic Integration uses, such as Craniosacral Therapy, to reverse the damage from the toxicities that cause Autism.http://www.TheVoiceOfHealthRadio.com

Today, I'm joined by the remarkable Dr. Lisa Koche, a leukemia survivor turned clinician who has spent her career bridging the worlds of conventional, functional, and quantum medicine. In our conversation, Dr. Koche opens up about her unique journey—from facing a life-altering cancer diagnosis at just fifteen, to questioning conventional medical dogma, to becoming a pioneer in mitochondrial health, personalized medicine, and nervous system regulation.   Episode Timestamps: Leukemia diagnosis and integrative healing journey ... 00:04:00 From patient to physician: asking “why” in medicine ... 00:07:00 Building collaborative, personalized care ... 00:11:00 Biohacking, mitochondria, and the limits of one-size-fits-all ...00:13:00 Wearables, nervous system, and self-assessment ... 00:18:00 Quantum biology, intuition, and energetic health ... 00:23:00 Supplements, subtle energy modalities, and future trends ... 00:32:00 Regenerative and mitochondrial testing advances ... 00:34:00 Nervous system regulation and the risk of overdoing biohacks ... 00:41:00 Guiding patients: self-awareness, nature, and media boundaries ... 00:44:00 Food, minerals, intention, and foundational self-care ... 00:55:00 Bridging science, energy, and personal sovereignty ... 01:00:00 A paradigm-shifting energy healing experience ... 01:02:00   Our Amazing Sponsors: Digestive Bitters by Just Thrive - One capsule before eating helps your body absorb more nutrients, ease digestion, and leave you feeling light instead of weighed down. Head over to Justthrivehealth.com/discount/NAT and use code NAT20 for 20% off.   NootroPept by LVLUP - an advanced cognitive enhancement formula that combines fast-acting neuropeptides, cholinergic support, and mitochondrial-boosting compounds to sharpen mental clarity, memory, and long-term brain performance. Visit https://lvluphealth.com/ and use code NAT at checkout for 20% off.    NMN+G Rx by Wizard Sciences - A scientifically formulated blend of NMN, ginsenosides from Panax ginseng, and apigenin. Together, they enhance mitochondrial function, boost NAD+ levels, and support cellular repair. Go to wizardsciences.com and look for NMN+G. Use code NAT15 at checkout to get 15% off your purchase.   Nat's Links:  YouTube Channel Join My Membership Community Sign up for My Newsletter  Instagram  Facebook Group

Dana Mooney, a mother of a 17-year-old autistic son, Preston, who has leukemia, stopped his chemotherapy treatment after eight months due to his declining health. She sought alternative treatments, finding a doctor who offered a plan based on genetic testing, which revealed a mutation preventing chemo absorption. Despite Preston's improvement on the alternative treatment, a referral was made against Dana, accusing her of mistreatment, and Preston was placed in state custody, requiring him to resume chemotherapy.   A mother was pressured by DHS and a caseworker to admit her autistic son to OU Children's Hospital, despite her concerns about the treatment plan and the hospital's financial incentives. The mother felt intimidated and coerced into signing paperwork, fearing separation from her son. The situation highlights the concerning power dynamics between state agencies, hospitals, and parents in medical decision-making.   Preston, a 17-year-old with autism, was taken into state custody after a caseworker, with a signed court order, tricked his mother, Dana, into handing him over. Despite Dana's objections and Preston's own wishes, the state administered chemotherapy and a blood transfusion, disregarding his preference for alternative medicine. The situation raises concerns about the lack of transparency and the power dynamics involved in such decisions.   Roberta Lewis observed a DHS-contracted sitter, hired through the company Synergy, who was unaware of the family's situation and only there to “sit.” The sitter's role was to observe the family, creating an intimidating environment and hindering open communication. Lewis questioned the purpose of these sitters, noting their lack of training, reporting responsibilities, and the potential misuse of taxpayer funds.   The state of Oklahoma is currently footing the bill for medical treatment for Preston, a child in DHS custody. This situation highlights the violation of parental authority and bodily autonomy, as well as the need for transparency in the court system and a new model for the DHS. The case is gaining national attention and may be the catalyst for change in the system.   Check out my sponsors!  Motus Health motushealth.com Stevens Trucking stevenstrucking.com  

Mom Curious is a weekly podcast produced by Hoff Studios in New York City, hosted by storyteller, actress, and thought leader Daniella Rabbani. Each episode dives into candid conversations about motherhood, womanhood, and the messy, magical spaces in between. With humor, honesty, and (you guessed it!) curiosity, Daniella sits down with women of all stripes to talk about what it really means to raise children—and ourselves—in today's world.About the Host:Daniella Rabbani (@DaniellaRabbani on Instagram) is a Brooklyn-based storyteller. On screen, she's appeared in HBO's Scenes from a Marriage, Amazon's The Better Sister, FX's The Americans, and films like Ocean's 8. On stage, she's headlined concerts worldwide, from Jazz at Lincoln Center in NYC to the State Jewish Theaters of Warsaw, Poland and Bucharest, Romania. She is also the voice behind national campaigns for Colgate, Starbucks, and Noom among others. Her award winning film OMA, inspired by her Holocaust survivor grandmother, can be seen on Amazon Prime.Through her podcast Mom Curious, Daniella blends her creative spirit and lived experience as a mother of two to spark conversations that are raw, hilarious, and deeply relatable. Her mission: to create a community where mothers (and those curious about motherhood) feel seen, supported, and inspired.This Week's Guest!Caitlin Murray is a humorist, content creator, writer, podcaster, mother of three and wife of one. She is the creator of Big Time Adulting. In 2016, Caitlin's oldest child was diagnosed with Leukemia at age three. Caitlin began sharing with family and friends about their journey and, specifically, her experience as a mother. Caitlin started her Instagram account in 2018 and has amassed over a million followers who appreciate her for her honest and humorous takes on motherhood. Her book comes out in 2026! Follow Caitlin at @bigtimeadulting on Instagram. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this week's episode we'll learn about targeting the tissue factor pathway inhibitor with a monoclonal antibody to rebalance HEMOSTASIS in hemophilia A and B. In the phase 3 BASIS trial, the monoclonal antibody marstacimab reduced bleeding events, and was generally well tolerated, with no unanticipated side effects. After that: matched-donor allogeneic CD19 CAR-T for adult B-ALL. Given after allogeneic transplantation, CAR-donor lymphocyte infusion after lymphodepleting chemotherapy was associated with favorable efficacy and a tolerable safety profile. Finally: a new prognostic index for mycosis fungoides and Sézary syndrome. Comprised of four prognostic factors, the “CLIPI” could enable more personalized treatment of cutaneous lymphomas, identifying patients who may benefit from intensified treatment.Featured ArticlesMarstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trialMatched donor allogeneic CAR-T for adult B-ALL: toxicity, efficacy, repeat dosing, and the importance of lymphodepletionA new prognostic index (CLIPI) for advanced cutaneous lymphoma enables precise patient risk stratification

In this How I Treat podcast episode, Laura Michaelis, MD interviews Sung-Yun Pai, MD about their recently published article in Blood journal "How I treat Wiskott-Alrich syndrome". They highlight recent updates in treatment, including new risk-benefit calculations due to safer treatments and longer follow-ups. Challenges include late diagnosis, lack of well-matched donors, and limited gene therapy availability. They emphasize the importance of early referral to specialized centers and the need for discussions about curative intent therapies, including transplant and gene therapy. The conversation also covers the complexities of gene therapy, such as the need for better conditioning agents and the challenges of achieving full correction in all cell types.

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Scott A. Armstrong, M.D., Ph.D., of the Dana-Farber Cancer Institute, studies how certain aggressive forms of acute myeloid leukemia (AML) develop and survive. His work centers on a protein called menin, which helps leukemia cells keep cancer-promoting genes switched on. Armstrong's team has found that blocking menin with specially designed drugs can shut down these gene programs, push leukemia cells to mature, and slow or stop the disease in lab models and patients. While some leukemias adapt by developing mutations in menin or finding other ways to survive, his research is revealing why certain genes are especially dependent on menin and how to target them more effectively. These discoveries are now shaping new treatments, drug combinations, and potential strategies for other cancers that rely on similar mechanisms. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 40875]

Help us end childhood Cancer here: https://fundraising.stjude.org/site/TR/Heroes/SJMMW?px=5816464&pg=personal&fr_id=158671©_link_share Ministry Spotlight: Partners 4 Africa- http://partners4africa.com/ Healing Hands International is a proud sponsor of this podcast. Get more info about them here: https://www.hhi.org/ Will shares info about our ministry spotlight on "Partners 4 Africa". Ben and Travis then discuss Travis' leukemia battle and practical ways to stay encouraged while facing trials and scary moments. The episode wraps up with the Healing Hands International Question of the Day. Links mentioned in this episode: Get our free ebook "28 Days of Focused Living" here: https://www.benandtravis.com https://www.facebook.com/groups/benandtravis Reframing Hope Book: https://www.benandtravis.com/books For extra content and material you can use for your family or ministry go to https://www.patreon.com/benandtravis Represent the show: https://www.benandtravis.com/store The Friday ReFresh: https://podcasts.apple.com/us/podcast/the-friday-refresh/id1611969995 Good Old Fashioned Dislike Podcast: https://podcasts.apple.com/us/podcast/good-old-fashioned-dislike/id1643163790 Co-Producers: Justin B., Doris C., Rhonda F., Scott K., Mary H., Scott B. This podcast is hosted by ZenCast.fm

On this now two year anniversary, I felt that this deserved a replay! This is an episode that is an enormous part of why I've changed the brand of the podcast to encompass the broader human experience. My daughter, Jocelyn, is my very special guest today. She talks about her leukemia diagnosis over two years ago, and the battle that would take up all of 2023, and change the way she has to look at her health for the rest of her life. Hearing this story from her provides so much joy for who she is as a woman, how she's grown, and my hope is that you'll hear the same message.  She shares some of the early indicators that were thought to be a bad case of the flu, the mysterious bruises she got, and when she checked in to Phoenix Children's Hospital. She talks about shaving her head, the incredible people that stepped up for her when she was down, and the quirky things that people say and do - when they don't know what to say or do! The lesson and ongoing message in this podcast for all of us is, I believe, that through struggle and adversity comes strength. I'm so proud of my daughter - and the lessons I believe are important for anyone struggling.  I hope that you find this episode to be uplifting and motivating for your own human experience. Thank you so much for listening! Stacie More episodes at StacieBaird.com.

Evening Prayer (people with leukemia) #prayer #pray #eveningprayer #jesus #god #holyspirit #aimingforjesus #healing #bible #love #peace #leukemia Thank you for listening, our heart's prayer is for you and I to walk daily with Jesus, our joy and peace aimingforjesus.com YouTube Channel https://www.youtube.com/@aimingforjesus5346 Instagram https://www.instagram.com/aiming_for_jesus/ Threads https://www.threads.com/@aiming_for_jesus X https://x.com/AimingForJesus Tik Tok https://www.tiktok.com/@aiming.for.jesus

In this week's episode, we'll learn more about relationships between Epstein-Barr virus genomic variants and human diseases, including hematological malignancies; the presence and timing of somatic GATA1 mutations and their relationship to a Down syndrome-specific form of leukemia; and new definitions for high-risk multiple myeloma that emphasize the presence of two or more high-risk cytogenetic abnormalities.Featured Articles:Association of Epstein-Barr virus genomic alterations with human pathologiesClinical significance of preleukemic somatic GATA1 mutations in children with Down syndromeBiallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myeloma

After experiencing stomach pains and fevers in the spring of 2023, Jordan Vanstee's then 2 year old son Kian was diagnosed with B Cell Acute Lymphoblastic Leukemia. Kian went through very difficult treatment at McMaster's Children's Hospital in Canada , but with the help of his Disney Hero Mickey Mouse and the Make a Wish Foundation, Kian is now in remission and is living his best life possible. 

In this episode of The Bloodline with Blood Cancer United, Elissa and guest co-host, Kristen Parker, speak with Dr. Anand […] The post Acute Promyelocytic Leukemia (APL): Advances, Hope, and Healing first appeared on The Bloodline with Blood Cancer United Podcast.

This episode of WNY Brews is brought to you by The Tap and Craft Festival at Buffalo Riverworks on October 4th, presented by The Lock Tender. Ticket information is available now at BuffaloBeerLeague.com/tapandcraft.This week, we've got a lot to raise a glass to. Hofbrauhaus Buffalo is celebrating five years with a big Bavarian bash, and Southern Tier Buffalo is hosting Pumkingfest with all the seasonal favorites and variants you could want. Wayland Brewing is throwing their third annual Oktoberfest weekend with music, food, steins and even axe throwing, while Buffalo Riverworks is gearing up for the Tap & Craft Festival with a stacked brewery list. Resurgence brings back the Dude's Homebrew Competition in support of the Leukemia & Lymphoma Society, Big Ditch is taking over taps at Nickel City Cigars, and Fattey Beer Co. just opened a new Amherst location. Plus, Bev Depot is hosting a fall tasting with samples from Mortalis, Big Ditch, Thin Man, and more.You can find all of these stories and more at BuffaloBeerLeague.com.WNY Brews is hosted by Scott Panfil and Brian Campbell. Reach us anytime at Brian@BuffaloBeerLeague.com and Scott@WNYBrews.com. Hosted on Acast. See acast.com/privacy for more information.

In this inspiring episode of The Van Deeb Podcast, Van sits down with long-time friend and powerhouse leader Sandy Spady — founder of Power Up Leadership and Women With Voices. Sandy shares her journey of building confidence in others, creating a thriving community of nearly 4,000 women, and making a difference through volunteer work and leadership coaching. From keynote speaking to fundraising for the Leukemia & Lymphoma Society, Sandy's passion for people shines through every story.

In this week's episode we'll learn about Azacitidine in VEXAS syndrome. Treatment can provide responses in patients with this complex autoinflammatory disorder. But relapse rates were high, so long-term therapy may be required to maintain disease control. After that: A step forward in precision blood matching. High-throughput array genotyping enables extended matching to reduce antibody formation. The results show the potential for reducing harm in regularly transfused patients. Finally, identifying a new vulnerability in TP53-mutated AML. Loss of the tumor suppressor BAP1 defines a unique subtype of TP53-mutated de novo AML. BAP1 loss also confers sensitivity to BCL-xL inhibitors in vivo, opening a new therapeutic avenue.Featured ArticlesEfficacy and safety of azacitidine for VEXAS syndrome: a large-scale retrospective study from FRENVEXArray genotyping of transfusion-relevant blood cell antigens in 6946 ancestrally diverse study participantsLoss of BAP1 defines a unique subtype of TP53-mutated de novo AML and confers sensitivity to BCL-xL inhibitors

In this Review Series episode, Associate Editor Dr. Hervé Dombret speaks with Dr. Mark Litzow about the latest immunotherapy advances for Acute Lymphoblastic Leukemia (ALL). The discussion highlights innovative treatments like blinatumomab and inotuzumab, which are showing remarkable success in clinical trials, including an 85% three-year survival rate and over 90% complete remission in elderly patients. Researchers are focusing on reducing chemotherapy intensity, developing personalized treatment approaches, and identifying optimal immunotherapy strategies for different ALL subtypes. The conversation underscores a promising shift towards more targeted, less toxic treatments that could significantly improve patient outcomes across various age groups and disease characteristics. These emerging therapies represent a potential paradigm shift in ALL treatment, offering hope for more effective and less aggressive therapeutic interventions.Read Dr. Litzow's paper “Incorporation of immunotherapy into frontline treatment for adults with B-cell precursor acute lymphoblastic leukemia” or find the whole review series on acute lymphoblastic leukemia in volume 145 issue 14 of Blood Journal. 

Dr. Lachelle Weeks is a physician-scientist at Dana-Farber Cancer Institute working on a project to predict leukemia risk based on widely available blood samples.

In this week's episode we'll learn about persistent changes in immune profiles in patients who have had diffuse large B-cell lymphoma, or DLBCL, and other cancers; that plasminogen activation and plasmin activity do not appear to play a role in routine physiological prevention of venous thromboembolism, or VTE; and about a novel mechanism that makes hematological malignancies carrying epigenetic mutations susceptible to PARP inhibitors.Featured Articles:Large B-cell lymphoma imprints a dysfunctional immune phenotype that persists years after treatmentPlasminogen activation and plasmin activity are not required to prevent venous thrombosis/thromboembolismTransposable elements as novel therapeutic targets for PARPi-induced synthetic lethality in PcG-mutated blood cancer

MD Anderson fellows discuss AML, MRD endpoints, and evolving trial strategies in a dynamic grand rounds–style presentation.

In this episode of Take the Stage, Brad Bialy sits down with Shad Tidler to explore how staffing and recruiting firms can prevent sales objections before they arise and leverage AI to build a smarter, more human sales process. About the Guest Shad, a seasoned member of the Lushin sales team since 2014, combines his extensive global business expertise with the disciplined mindset of an Ironman triathlete. Specializing as a leading sales transformation consultant, he is known for crafting scalable strategies and processes tailored for client success. Shad's structured approach instills a sense of calm in clients, guiding them past immediate challenges and toward their goals. Beyond his professional pursuits, Shad enjoys swimming, biking, running, practicing martial arts, and traveling. He actively contributes to his community by volunteering at his local church, mentoring individuals within and outside his organization, and supporting the Leukemia and Lymphoma Society. However, above all else, Shad values his role as a devoted husband and friend. Key Takeaways Objections reveal problems earlier in the process. Desperation kills trust in sales. Sales is a series of small agreements. Abundance beats scarcity in prospecting. AI is a tool, not the solution. Timestamps [00:20] – Why objections mean you're already too late [02:50] – The trap of “we're different” pitches [05:11] – Shifting from qualifying in to disqualifying out [07:13] – Sales as small agreements, not one-call closes [09:43] – Letting prospects define next steps [11:44] – The roots of desperate selling [13:59] – Relationship analogies for rejection in sales [17:02] – Why being okay with “no” creates momentum [20:30] – Building structure around prospect follow-up [23:37] – Giving junior reps permission to experiment [27:17] – How AI is disrupting sales conversations [30:22] – Where staffing leaders should begin with AI About the Host Brad Bialy is a trusted voice and highly sought-after speaker in the staffing and recruiting industry, known for helping firms grow through integrated marketing, sales, and recruiting strategies. With over 13 years at Haley Marketing and a proven track record guiding hundreds of firms, Brad brings deep expertise and a fresh, actionable perspective to every engagement. He's the host of Take the Stage and InSights, two of the staffing industry's leading podcasts with more than 200,000 downloads. Sponsors and Offers Heard Take the Stage is presented by Haley Marketing. The old way of selling staffing is dead. Let's fix it – with smarter strategies and HUGE DISCOUNTS on modern lead gen tools: https://bit.ly/Bialy20 Book a 30-minute business and marketing consultation with host, Brad Bialy: https://bit.ly/Bialy30 For 30 years, Benefits in a Card has delivered benefit plans designed specifically for the staffing industry—over 140 unique options with immediate coverage, unique perks like FreeRx, and solutions that reduce turnover while improving ACA compliance. Give your workforce benefits they'll actually use and give your staffing firm a competitive edge. Learn more at https://www.BenefitsInACard.com.

In this moving episode of Supply Chain Now, host Scott Luton sits down with Kristi Porter, Adrian Purtill, and Enrique Alvarez of Vector Global Logistics to explore a powerful story of purpose and community. Adrian shares a deeply personal initiative in honor of his late ex-wife, Kathy Purtill, who bravely battled leukemia. To carry her legacy forward, their son Kieran is climbing Mount Kilimanjaro to raise funds for the Leukemia & Lymphoma Society.This conversation goes beyond logistics, shining a light on the value of giving forward, building community, and leading with purpose. The Vector Global Logistics team reflects on how purpose-driven action can change lives—both in the global supply chain and beyond.Learn how you can support Kieran's mission, and be inspired to embrace the power of relationships, resilience, and purpose.Additional Links & Resources:Kathy Purtill's fundraising page for The Leukemia and Lymphoma Society: https://diy.lls.org/fundraiser/6467059Connect with Enrique: https://www.linkedin.com/in/enrique-alvarez-64332a2/Connect with Kristi: https://www.linkedin.com/in/kporter9876/Connect with Adrian: https://www.linkedin.com/in/adrian-purtill-947a2b5/Learn more about Vector Global Logistics: https://vectorgl.com/Learn more about Logistics with Purpose: https://logisticswithpurpose.co/Learn more about Supply Chain Now: https://supplychainnow.comWatch and listen to more Supply Chain Now episodes here: https://supplychainnow.com/program/supply-chain-nowSubscribe to Supply Chain Now on your favorite platform: https://supplychainnow.com/joinWork with us! Download Supply Chain Now's NEW Media Kit: https://bit.ly/3XH6OVkWEBINAR- Mastering Data in the AI Explosion Age - Managing the Fuel That Powers Innovation: https://bit.ly/4ogPN1kWEBINAR- Real stories: Fast-tracking value, a pioneering digital transformation with impactful results.: https://bit.ly/4mgp1EWWEBINAR: Real Shipping Stories. Real Money Saved.: https://bit.ly/45PegUmWEBINAR: From Compliance to Impact and Competitive Advantage: How to Decarbonize Your Supply Chain: https://bit.ly/47uXKKoThis episode is hosted by Scott Luton and produced by Trisha Cordes, Joshua Miranda, and Amanda Luton. For additional information, please visit our dedicated show page at: https://supplychainnow.com/honoring-legacy-moving-climbing-mountains-1473